- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07363876
L'efficacité de l'ultrasonication en combinaison avec l'injection intra-articulaire de corticostéroïdes pour l'arthrite
L'Efficacité de l'Ultrasonication en Combinaison Avec l'Injection Intra-articulaire de Corticostéroïdes pour l'Arthrite
This study investigates whether ultrasound therapy applied prior to intra-articular corticosteroid injection can enhance the treatment efficacy for patients with joint arthritis and assess its safety. Adult patients diagnosed with arthritis in the limbs who are indicated for corticosteroid injection are eligible, while patients with joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis are excluded.
Ultrasound therapy is a valuable physical therapy tool for musculoskeletal diseases, producing therapeutic effects through thermal and non-thermal mechanisms. It can improve tissue extensibility, reduce joint stiffness, increase local blood flow, enhance metabolism during tissue repair, and facilitate drug absorption. This study evaluates whether applying ultrasound before intra-articular corticosteroid injection improves therapeutic outcomes in patients with arthritis, and assesses the safety of this combined intervention. Patients aged 18 or older, diagnosed with limb arthritis, and indicated for corticosteroid injection are eligible. Exclusion criteria include joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis at the treatment site.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Kuo-Lung Lai, MD
- Numéro de téléphone: +886-4-2359-2525
- E-mail: kllaichiayi@yahoo.com.tw
Lieux d'étude
-
-
-
Taichung, Taïwan, 407219
- Recrutement
- Taichung Veterans General Hospital
-
Contact:
- Kuo-Lung Lai, MD
- Numéro de téléphone: +886-4-2359-2525
- E-mail: kllaichiayi@yahoo.com.tw
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adults aged 18 years or older.
- Diagnosed with arthritis in the limbs.
- Inadequate response to or contraindication for oral anti-inflammatory medications.
- Assessed by a physician as requiring intra-articular corticosteroid injection.
Exclusion Criteria:
- History of joint replacement (prosthetic joint) in the affected area.
- Hip joint involvement.
- Diagnosis of gout.
- Infectious arthritis.
- Presence of cellulitis at the treatment site.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: ultrasonication en combinaison avec une injection intra-articulaire de corticostéroïde
|
Therapeutic Ultrasound (TUS) is a non-invasive treatment widely used in physical medicine and rehabilitation for musculoskeletal conditions. Since its introduction in the mid-20th century, TUS has gained popularity in clinical practice due to its ability to penetrate tissues, target treatment areas precisely, and exhibit minimal side effects. This study aims to investigate the mechanisms of action, clinical efficacy, and safety of therapeutic ultrasound in musculoskeletal therapy. Injection of triamcinolone (3-50 mg depending on joint size) into the affected joint. Administered once per participant. |
|
Comparateur actif: injection intra-articulaire de corticostéroïde
|
Injection of triamcinolone (3-50 mg depending on joint size) into the affected joint. Administered once per participant. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Reduction in Synovial Swelling Area Assessed by Joint Ultrasound
Délai: From enrollment to the end of treatment at 2 weeks
|
Synovial swelling area (pixels) assessed by joint ultrasound. A treatment response is defined as a ≥50% reduction in synovial swelling area from baseline. |
From enrollment to the end of treatment at 2 weeks
|
|
Change in Power Doppler (PD) Score of the Target Joint
Délai: From enrollment to the end of treatment at 2 weeks
|
Power Doppler (PD) score (range 0-3) of the target joint assessed by joint ultrasound. A treatment response is defined as a PD score of 0 at 2 weeks post-treatment. |
From enrollment to the end of treatment at 2 weeks
|
|
Change in Pain Visual Analogue Scale (VAS)
Délai: From enrollment to the end of treatment at 2 weeks
|
Pain intensity assessed using a visual analogue scale (VAS 0-10). A treatment response is defined as a ≥50% reduction in VAS score from baseline or a VAS score ≤1 at 2 weeks post-treatment. |
From enrollment to the end of treatment at 2 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Absence of Synovitis Recurrence Based on Power Doppler (PD) Score
Délai: From enrollment to 3 months post-treatment
|
Absence of synovitis recurrence assessed by Power Doppler (PD) ultrasound. Recurrence is defined as any increase in PD score compared with the 2-week post-treatment assessment. |
From enrollment to 3 months post-treatment
|
|
Absence of Synovial Swelling Recurrence on Gray-Scale Ultrasound
Délai: From enrollment to 3 months post-treatment
|
Absence of synovial swelling recurrence assessed by gray-scale ultrasound. Recurrence is defined as an increase in synovial swelling area of ≥20% compared with the 2-week post-treatment assessment. |
From enrollment to 3 months post-treatment
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Kuo-Lung Lai, MD, Taichung Veterans General Hospital (TaichungVGH)
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- TCVGH-1150801B
- CF25511A (Autre identifiant: TCVGH IRB)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .